VivoSim Labs (VIVS) Stock Price, News & Analysis

Company Overview

VivoSim Labs, Inc. (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology. These platforms support a range of applications from high-throughput screening and mechanism-of-action studies to personalized medicine initiatives, allowing pharmaceutical and biotechnology customers to accelerate research timelines and reduce reliance on animal testing. VivoSim Labs also offers custom assay development, contract research services, and collaborative partnerships to address unique project requirements.

Founded to leverage advances in cellular biology and biofabrication, VivoSim Labs has positioned itself as an innovator in the life sciences tools market. Headquartered in the United States, the company serves a global customer base spanning North America, Europe and Asia. With a focus on expanding its product pipeline, scaling manufacturing capabilities and forging strategic alliances, VivoSim Labs aims to enhance the predictability of preclinical studies and drive more efficient drug development pathways.

Key Stats

• Today's Range: $1.13 to $1.21
• 50-Day Range: $1.19 to $1.71
• 52-Week Range: $1.13 to $5.30
• Volume: 36,182 shs
• Average Volume: 957,059 shs
• Market Capitalization: $3.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

VivoSim Labs Stock Analysis - MarketRank™

VivoSim Labs scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

VivoSim Labs has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

VivoSim Labs has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of VivoSim Labs is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VivoSim Labs is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

VivoSim Labs has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.58% of the float of VivoSim Labs has been sold short.

Short Interest Ratio / Days to Cover

VivoSim Labs has a short interest ratio ("days to cover") of 1.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VivoSim Labs has recently decreased by 23.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VivoSim Labs does not currently pay a dividend.

Dividend Growth

VivoSim Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for VIVS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added VivoSim Labs to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VivoSim Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.50% of the stock of VivoSim Labs is held by insiders.

Percentage Held by Institutions

8.23% of the stock of VivoSim Labs is held by institutions.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 6/09/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIVS
• CIK: 1497253
• Web: N/A
• Phone: (858) 224-1000
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.48 million
• Net Margins: -861.27%
• Pretax Margin: -862.68%
• Return on Equity: -15.51%
• Return on Assets: -11.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.44
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $140 thousand
• Price / Sales: 21.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.54 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 2,610,000
• Free Float: 2,543,000
• Market Cap: $3.08 million
• Optionable: N/A
• Beta: 1.38